Pharmacogenomics and Biomarker-Guided Psychotropic Drug Development in Treatment-Resistant Depression

Background: Treatment-Resistant Depression (TRD) is usually framed as a prescribing problem. This perspective also considers it as a drug-development problem, because diagnostic categories may conceal biological differences relevant to treatment response. Scope: We examine five dimensions relevant to psychotropic drug development in TRD: pharmacogenomic variation in exposure, pharmacodynamic target engagement, inflammatory and immunometabolic state, polygenic liability, and anhedonia and reward function. Each is linked to a biological or clinical readout, a development decision, and a medicinal-chemistry implication. Tolerability is treated as a design priority alongside efficacy. We discuss relationships between dimensions, trial design, regulatory requirements, and limitations, distinguishing established exposure tools from candidate predictors of differential treatment benefit. Conclusion: Biomarker-informed development could improve the testing of mechanistically targeted treatments, but the integrated framework remains unvalidated. Genotype requires measured exposure, target engagement does not establish clinical efficacy, and candidate response markers require prospective randomized evaluation. Early development should test these assumptions before a marker defines a confirmatory population or prescribing indication.